RISK11
transcriptomic signature scores for 20,207 volunteers who were screened at five
geographically diverse sites across South Africa. Signature scores were
computed from QC'ed gene expression measurements performed by
microfluidic RT-qPCR on mRNA derived from whole blood collected in
PAXgene tubes. Participants were randomised into three groups
and followed-up for 15 months to evaluate diagnostic and prognostic
performance of RISK11 and to evaluate efficacy of high-dose isoniazid
and rifapentine for prevention of incident TB.
Funding
Bill & Melinda Gates Foundation (OPP1116632, OPP1137034)
Strategic Health Innovation Partnerships Unit of the South African Medical Research Council